ProTgen, Inc. creates off‑the‑shelf progenitor T (ProT) cells from a universal iPSC source to rapidly restore functional T‑cell immunity in patients whose cancer treatments have compromised their immune systems. The scalable, cost‑effective cell‑therapy platform is designed for use after hematopoietic stem cell transplantation and in solid‑tumor immunotherapy, with potential applications in autoimmune diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer therapies such as chemotherapy, radiation, and hematopoietic stem cell transplantation often cause prolonged impairment of T‑cell immunity. Incomplete immune recovery reduces the effectiveness of subsequent treatments and increases patients’ risk of relapse and opportunistic infections.
Solution
ProTgen has developed a cell‑therapy platform that produces off‑the‑shelf progenitor T (ProT) cells designed to reconstitute functional T‑cell immunity. The ProT cells are generated from a universal induced pluripotent stem cell (iPSC) source, enabling scalable manufacturing and lower cost compared with autologous CAR‑T products. By delivering these progenitor cells, the platform aims to accelerate immune reconstitution after hematopoietic stem cell transplantation and enhance anti‑tumor immunity in solid‑tumor settings. The approach is positioned for broader applications, including autoimmune disorders, by restoring the immune system’s “master organ.” Early clinical milestones are planned to de‑risk the technology, with first‑in‑human trials targeted for 2027.
Target Audience
Primary customers are oncology and transplant centers seeking to improve post‑treatment immune recovery, as well as pharmaceutical partners developing immuno‑oncology and autoimmune therapeutics.
Features
- Universal iPSC‑derived progenitor T cells that can be manufactured at scale and stored off‑the‑shelf
- Off‑the‑shelf product eliminates the need for patient‑specific cell processing, reducing cost and turnaround time
- ProT cells differentiate in vivo into functional naïve and memory T‑cell subsets, promoting durable immune reconstitution
- Platform designed for compatibility with allogeneic hematopoietic stem cell transplantation and solid‑tumor immunotherapy regimens
- Potential to extend therapy to autoimmune disease indications by modulating immune competence